Shots:

• The P-III IMbrave150 study involve assessing of Tecentriq (1200 mg on day 1 of each 21-day cycle) in combination with Avastin (15 mg/kg on day 1 of each 21-day cycle) vs SoC sorafenib in 501 patients in a ratio (2:1) with unresectable HCC with no prior treatment with systemic therapy
• The P-III III IMbrave150 study resulted in meeting its co-1EPs demonstrating improvement in OS and PFS- no new safety signals were observed
• The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq's ability to restore anti-cancer immunity- by inhibiting VEGF related immunosuppression. The results from the study will be submitted to health authorities globally- including the US FDA- EMA & NMPA

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche